×
Senti Biosciences Operating Expenses 2022-2024 | SNTI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Senti Biosciences operating expenses from 2022 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Senti Biosciences Operating Expenses 2022-2024 | SNTI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Senti Biosciences operating expenses from 2022 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$158.3B
Bristol Myers Squibb (BMY)
$119.4B
Vertex Pharmaceuticals (VRTX)
$116.1B
Gilead Sciences (GILD)
$112.4B
CSL (CSLLY)
$87.2B
Regeneron Pharmaceuticals (REGN)
$81.1B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.6B
Alnylam Pharmaceuticals (ALNY)
$31.6B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$23B
Illumina (ILMN)
$22.2B
BeiGene (BGNE)
$18.6B
Moderna (MRNA)
$15.8B
Incyte (INCY)
$13.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.2B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.1B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.9B